Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

BASEL, Switzerland – 5th November 2018
Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.

John is an accomplished executive leader with more than 25 years’ experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries. In this capacity, he has a depth and breadth of expertise involving academic institutions and biotech and pharmaceutical companies of all stages, including financing, acquisitions, R&D collaborations and in-licensing agreements, among others. John currently serves as Corporate VP, Global Business Development at Novo Nordisk, and before this he was VP Business Development at Biogen Inc., Managing Director at the healthcare investment firm MPM Capital, and VP Business Development at Millennium Pharmaceuticals.

Alfredo Nicosia, Chief Executive Officer of Nouscom, said: “As a respected executive leader, John is an outstanding addition to the Nouscom Board. We are fortunate to have attracted such talent to our Board of Directors and we look forward to working with him and drawing upon his extensive networks and global business development experience.”

John McDonald commented on his appointment: “I’m excited to join the Nouscom Board at a pivotal time in the clinical development of Nouscom’s oncology vaccine candidates. I look forward to being a part of the team that advances this important work.”

John graduated from the University of California, Berkeley, with a B.S. in Business Administration and M.B.A., and the University of California, Hastings College of the Law, with a J.D.  He practiced as a certified public accountant and is a member of the California State Bar.

Recent Posts